*Toxoplasma gondii* is an apicomplexan protozoan that infects humans and domesticated animals. Infection by *T. gondii* presents major health concerns in immunocompromised patients.^[@ref1]^ Current therapies have some shortcomings,^[@ref2]^ thus new and effective therapy for treating *T. gondii* infection is needed.

The life cycle of *T. gondii* is regulated in part by a family of calcium-dependent protein kinases (CDPKs) that have no direct homologues in humans.^[@ref3],[@ref4]^*T. gondii* CDPK1 (*Tg*CDPK1) has been shown both genetically and chemically to be critical for parasite reproduction, specifically in the process of cell invasion and egress.^[@ref3],[@ref5]−[@ref7]^ Furthermore, *Tg*CDPK1 contains a glycine residue at the "gatekeeper" position, which is extremely rare for mammalian kinases.^[@ref8]−[@ref10]^ The critical role of CDPK1 in combination with its unique active site gatekeeper makes this kinase an attractive target for antiparasitic drug discovery.^[@ref3],[@ref8],[@ref9],[@ref11]−[@ref13]^ Three different chemical scaffolds of CDPK1 inhibitors have been reported previously: the pyrazolopyrimidine (PP) scaffold,^[@ref14]−[@ref17]^ the acylbenzimidazole scaffold,^[@ref18],[@ref19]^ and the 5-aminopyrazole-4-carboxamide (AC) scaffold.^[@ref20]^ Overexpression of CDPK1 with a methioinine replacing the glycine mutant conveys resistance to certain inhibitors based on the PP scaffold.^[@ref8]^ However, it should be recalled that *T. gondii* is not transmitted from person to person (except in rare congenital acquisition), so that should resistant parasites arise, they would be confined to the treated individual. Preliminary structure--activity relationship (SAR) studies of the AC scaffold found a promising inhibitor (**1**, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) which inhibited *Tg*CDPK1 with an IC~50~ value of 2.0 nM and exhibited 0.22 μM EC~50~ in the *T. gondii* cell assay.^[@ref20]^ However, its relatively low solubility, short half-life, and relatively high oral clearance could limit its further development. In this report, we describe further SAR studies of the AC scaffold based on compound **1**, which resulted in the discovery of compounds with improved aqueous solubility, potency, and/or pharmacokinetic (PK) properties.

In the previous study most variations at N1 position were carried out with Ar~1~ (on C3) being fixed as 2-naphthyl group, and for analogues containing other heteroaryl groups C3, only *t*-butyl analogues at N1 position were made.^[@ref20]^ Therefore, we reinvestigated a larger panel of N1 substitutions, while first fixing a 7-ethoxyquinolin-3-yl group at C3 ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Compounds with aliphatic chains (**2**--**5**) or rings (**6**--**11**) at the N1 position did not improve enzyme potency over **1**. Hydroxyl aliphatic chains were also introduced to decrease lipophilicity of compounds, resulting in compounds (**13**--**16**) with comparable activity relative to the hydroxyl-free compounds. Though the potency did not improve during the investigation of the N1 substitutions, some of the substituents, especially the hydroxyl aliphatic chains, improved the solubility of compounds and provided the opportunity to optimize the PK properties. Additional study of N1 substitutions was conducted with a 2-ethoxyquinolin-6-yl group at C3. All the compounds (**17**--**22**) exhibited low nanomolar potency against *Tg*CDPK1, indicating that the quinolin-6-yl moiety was as well accommodated in the hydrophobic pocket as the quinolin-3-yl. These two Ar~1~ alternatives may lead to potent compounds with different pharmacological properties.

###### SAR Study of N1-Substitution
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Because the *t*-butyl group seems to be the optimal N1 substitution, it was fixed at the N1 position, while we investigated the C3 substituent ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) with the goal to optimize PK properties. Replacement of the ethoxy group on the 7-position of the quinolin-3-yl with fluorine, chlorine, trifluoromethyl, or alkane groups all produced decreased potency (**23**--**26**). Coming back to the alkoxy substitutions, small sized chain- or ring-alkoxy groups were potent inhibitors (**28**, **31**, **34**, and **36**), while the trifluoromethoxyl led to decreased activity. Similarly, the quinolin-7-yl analogues with 2-cyclopropoxy and 2-cyclobutoxy substitutions (**35** and **37**) were also potent for *Tg*CDPK1 inhibition.

###### SAR Study of C3-Substitution
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The consistent binding pose of the AC scaffold in the presence of chemical elaboration at Ar~1~ and R~2~ was confirmed by crystal structures of selected compounds bound to *Tg*CDPK1. In detail, the amine group and the oxygen atom of the amide group make hydrogen bonds to the hinge region of *Tg*CDPK1, projecting the Ar~1~ group at the C3 position into the hydrophobic pocket adjacent to the gatekeeper residue and the R~2~ group at the N1 position into the ribose-binding pocket. In particular the bound position of the Ar~1~ quinoline is not significantly perturbed by the position of the ring N, but its precise orientation is constrained by the need to accommodate a distal cyclopropyl (compounds **34** and **35**) or cyclobutyl (compounds **36** and **37**) between *Tg*CDPK1 residues Leu 114 and Leu 198 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Co-crystallizations and structure determinations were performed as previously described.^[@ref14],[@ref20]^ Crystal structures showing the bound state of compounds **1** and **37** have been deposited in the PDB (entry codes 4ONA and 4YJN).

![Superposition of crystal structures of *Tg*CDPK1 in complex with **1** (gold) and **37** (blue).](ml-2015-00319p_0007){#fig1}

A select group of potent inhibitors were evaluated in a variety of assays to assess aqueous solubility (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.5b00319/suppl_file/ml5b00319_si_001.pdf)), selectivity over mammalian kinases, potency against parasite cells, cytotoxicity to mammalian cells ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}), and, for select compounds, PK properties after oral (PO) dosing in mice ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}).

###### Comprehensive Evaluation of Top Inhibitors[a](#t3fn1){ref-type="table-fn"}

  compd number   SRC IC~50~ (μM)   *T. gondii* EC~50~ (μM)   cytotoxicity (μM)                    compd number   SRC IC~50~ (μM)   *T. gondii* EC~50~ (μM)                cytotoxicity (μM)
  -------------- ----------------- ------------------------- ------------------------------------ -------------- ----------------- -------------------------------------- -------------------
  **1**          \>30              0.22 ± 0.09               **\>**30                             **21**         ND                0.32 ± 0.02                            ND
  **2**          \>30              0.72 ± 0.10               ND[b](#t3fn2){ref-type="table-fn"}   **22**         \>10              0.21 ± 0.04                            \>40
  **6**          \>10              1.21 ± 0.14               \>40                                 **23**         \>30              2.25 ± 0.94                            \>40
  **7**          \>10              0.52 ± 0.003              \>40                                 **28**         \>30              0.40 ± 0.04                            \>40
  **8**          \>10              0.97 ± 0.40               \>40                                 **30**         ND                1.21 ± 0.42                            \>40
  **9**          \>10              0.33 ± 0.07               ND                                   **31**         \>10              0.69[c](#t3fn3){ref-type="table-fn"}   \>40
  **11**         \>10              0.41 ± 0.0                \>40                                 **32**         \>10              1.47[c](#t3fn3){ref-type="table-fn"}   \>40
  **16**         \>10              1.19 ± 0.14               \>40                                 **34**         4.75              0.42 ± 0.10                            \>40
  **17**         \>10              0.20 ± 0.09               \>40                                 **35**         \>10              0.089 ± 0.044                          \>40
  **18**         3.3--10           0.14 ± 0.003              \>40                                 **36**         \>10              0.48 ± 0.09                            \>40
  **19**         \>10              0.48 ± 0.07               \>40                                 **37**         \>10              0.48 ± 0.06                            \>40
  **20**         \>10              0.43 ± 0.01               \>40                                                                                                          

Selectivity at enzyme level was conducted using a human kinase (SRC) that has a small gatekeeper residue; efficacy against parasites was performed using a *T. gondii* growth assay,^[@ref15]^ values shown are the average ± standard deviation from two or more experiments; and cytotoxicity to mammalian cells was measured using the CRL-8155 cell line. Experimental details are provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.5b00319/suppl_file/ml5b00319_si_001.pdf).

ND: not determined.

Value from one experiment.

As a preliminary evaluation of the selectivity of the AC analogues, the top compounds were tested for inhibition of the human kinase SRC that contains a small gatekeeper residue using reported procedures.^[@ref16]^ As shown in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, none of the top compounds except compounds **18** and **34** displayed significant inhibition of SRC activity at concentrations up to 10 μM. Though compound **34** showed an IC~50~ of SRC inhibition at 4.75 μM, the selectivity of *Tg*CDPK1 over SRC was more than 450-fold.

We investigated the efficacy of compounds against *T. gondii* cells ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). With 7-ethoxyquinolin-3-yl at C3 position, the modification of the *t*-butyl group merely resulted in reduced potency compared to **1**. However, the C3 2-ethoxyquinolin-6-yl compounds were generally more potent than their 7-ethoxyquinolin-3-yl analogues, while compounds **18**, **17**, and **22** exhibited comparable potency to **1**. Modification of the 7-ethoxy group of quinolin-3-yl moiety resulted in compounds mostly with lower potency. Even the best compounds with this modification, the cyclopropoxy (**34**) and cyclobutoxy (**36**) substituted analogues, showed at least 2-fold less potency compared to **1**. Interestingly, for the last two quinoline pairs in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, while the cyclobutoxy substituted pairs (**37** and **36**) showed similar potencies, the cyclopropoxy substituted pairs (**35** and **34**) were quite different, as **35** was ∼5-fold more potent than **34**. Compound **35** was the most potent inhibitor found in this study, with increased activity against parasites compared to **1**. As an indicator of selectivity at cellular level, we measured the cytotoxicity of these inhibitors ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}) using human lymphocyte cell line (CRL-8155).^[@ref16]^ These compounds showed no significant inhibition of cell growth at concentrations up to 30 or 40 μM.

###### PK Profiles for Select Inhibitors[a](#t4fn1){ref-type="table-fn"}

  compd   *C*~max~ (μM)   *T*~max~ (min)   AUC (μM·min)   CL (mL/min/kg)   *T*~1/2~ (min)
  ------- --------------- ---------------- -------------- ---------------- ----------------
  1       9.9 ± 2.9       60 ± 52          2428 ± 277     11.8 ± 0.5       88 ± 19
  9       4.6 ± 1.0       80 ± 35          1608 ± 182     16.4 ± 1.5       204 ± 34
  17      5.3 ± 0.6       80 ± 35          1694 ± 379     16.7 ± 3.8       134 ± 28
  22      2.4 ± 2.0       30 ± 17          140 ± 97       186 ± 75         \<30
  32      7.1 ± 0.6       140 ± 92         3713 ± 1073    7.1 ± 0.7        549 ± 131
  34      23.4 ± 3.1      130 ± 17         18450 ± 470    1.4 ± 0.04       290 ± 48
  35      3.2 ± 0.7       160 ± 69         2676 ± 784     10.7 ± 1.0       559 ± 209
  36      4.1 ± 1.5       30 ± 0           458 ± 206      57 ± 4           42 ± 17

Mice dosing at 10 mg/kg, po. Reported as average ± standard deviation of measurements from three mice.

Select compounds were subjected to PK studies in mice following oral administration at 10 mg/kg ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). Compounds **9** and **17** had a higher oral clearance than compound **1** resulting in lower maximum concentration (*C*~max~) and total exposure (area under the curve, AUC) compared to **1**. This is likely due to lower bioavailability of compounds **9** and **17** as their half-lives were longer than that of compound **1**. Compound **22** had greatly improved solubility but had nearly 16-fold higher oral clearance than compound **1** resulting in significantly diminished *C*~max~ and AUC in comparison to **1**. Compound **32** exhibited improved PK profile though the potency is relatively poor. Other analogues with small alkyl rings on quinoline oxygen are **34** and **36** and their quinolin-6-yl counterparts **35** and **37**. While the cyclobutoxy compound **36** with poor solubility did not show improvement on PK properties, the cyclopropoxy compound **34** with improved solubility did show a significantly improved PK profile. The oral clearance of compound **34** (1.4 mL/min/kg) was the lowest of the tested compounds and about 8-fold lower than that of compound **1** (11.8 mL/min/kg). This decrease in CL was associated with a 3-fold longer half-life and 2.3-fold higher *C*~max~. The exposure of compound **34** was 8-fold higher ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) in comparison to **1** likely due to both better bioavailability and lower systemic clearance ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The PK profile of **35** was similar to **1** in terms of AUC and oral clearance (10.7 mL/min/kg). However, **35** is still promising considering its much longer *T*~1/2~ (559 min) compared to **1** (88 min) and **34** (290 min) and its high potency against *T. gondii* (EC~50~ = 0.089 μM). The human plasma protein binding properties of these three compounds were also measured, and all three compounds showed low protein binding with unbound fractions of 57% for **1**, 84% for **34**, and 88% for **35**. Based on the overall properties, **34** and **35** were selected for testing in a mouse model of *T. gondii* infection in comparison to **1**. All the three compounds get into the CNS, as estimated by a single time point, comparing plasma with brain tissue concentrations, where we found a brain/plasma ratio of 15.8% for **1**, 16% for **34**, and 43% for **35**.

![Comparison of oral PK curves of compounds **1**, **34**, and **35**.](ml-2015-00319p_0008){#fig2}

![Efficacy of **1**, **34**, and **35** evaluated by measurement of *T. gondii* in peritoneal fluid, spleen, and brain. Mice were analyzed 1 day after the last dose. Groups consisted of 4 mice. (A) Efficacy of compound **1**, peritoneal parasite count. Due to its short half-life **1** was dosed twice daily. The higher dose reduced parasites by \>10-fold compared to controls. Efficacy of compounds **34** and **35** (single daily dose): (B) peritoneal parasite count, (C) qRTPCR of spleen, and (D) qRTPCR of brain. The differences between all treatment groups and their respective controls and the difference between **34** and **35** on peritoneal *T. gondii* infection were statistically significant, while the differences between all other compared treatment groups were not statistically significant using a *p*-value of \<0.05. Bars represent the mean and the standard error of the mean. PEG = polyethylene glycol; mpk = mg/kg; qRTPCR = quantitative real-time PCR. \*Three mice in **35**, 50 mg/kg group were analyzed.](ml-2015-00319p_0009){#fig3}

*In vivo* efficacy of **34** and **35** was tested using a model of acute *T. gondii* infection with the Type I RH strain that is uniformly fatal in mice. Treatment was started 2 days after *T. gondii* inoculation to allow establishment of a robust systemic infection.^[@ref21]^ Compounds **1**, **34**, and **35** were administered via oral (po) dosing for 5 days. Compound **1** significantly reduced *T. gondii* infection ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). However, **34** and **35** were much more efficacious than **1**, reducing *T. gondii* in the peritoneal fluid and spleen to near-undetectable levels at comparable or lower does than **1** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B,C). Compound **34**, given at 50 mg/kg and 20 mg/kg, reduced the mean concentration of *T. gondii* in the peritoneal fluid by 99.6% and 93.4%, respectively. Compound **35**, given at 20 mg/kg, decreased *T. gondii* below the limits of detection (\<100 parasites/mL). Similarly, **34** and **35** reduced the mean number of *T. gondii* in the spleen to less than 1% of controls. Both compounds also demonstrated more than 5-fold reduction in the mean concentration of detectable *T. gondii* DNA in the brain, suggesting that either both **34** and **35** achieve brain concentrations during active infection that are sufficient to inhibit *T. gondii* replication or **34** and **35** prevent brain infection from progressing by inhibiting systemic toxoplasmosis. None of the treated mice showed signs of infection or toxicity such as weight loss, altered grooming, or lethargy. However, one mouse in the **35**, 50 mg/kg group died on the fifth day of treatment, but the cause of death was not established. Based on the elimination of *T. gondii* in the peritoneal fluid by **35** and the trends of better efficacy in the brain and spleen, it appears that **35** is more potent than **34**. These experiments demonstrate that **34** and **35** are highly active against fulminant experimental toxoplasmosis.

Additional studies were performed using these two lead compounds **34** and **35** to address (1) the selectivity of AC series analogues beyond the single human kinase SRC in the preliminary study and (2) if the inhibitors acted on-target in parasite cells. For selectivity, we performed a fluorescence based binding inhibition assay as previously described^[@ref22]^ using a panel of ∼80 diverse human kinases.^[@ref23]^ Compound **34** did not show any IC~50~ below 1 μM. Compound **35** only showed IC~50~s below 1 μM for three of the 80 kinases (0.2--0.5 μM). This indicated that the top two compounds are quite selective against *Tg*CDPK1. A table of the binding inhibition results covering a selected group of 20 kinases is provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.5b00319/suppl_file/ml5b00319_si_001.pdf).

To study if the inhibitors acted on-target in parasite cells, we compared parasite growth inhibition against the parental cell line, a cell line transfected with a *Tg*CDPK1 expression plasmid, and a cell line transfected with a similar expression plasmid bearing CDPK1 with a G128M mutation at the gatekeeper position as described previously.^[@ref8]^ The results (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.5b00319/suppl_file/ml5b00319_si_001.pdf) for additional figures) showed that neither **34** nor **35** produced significant shifts in parasite growth inhibition at low compound concentrations. However, these two compounds could not completely suppress parasite growth at high concentrations in the cell line containing the G128M mutant of *Tg*CDPK1. This suggests that the two leads only acted partially on-target, and therefore, testing AC series inhibitors with weaker IC~50~ against *Tg*CDPK1 may still lead to potent inhibitors at the parasite level. Additional study will be required to identify other potential cellular targets of the AC series inhibitors.

In summary, we described the structural optimization of 5-aminopyrazole-4-carboxamide derivatives as *Tg*CDPK1 inhibitors based on compound **1**. We evaluated over 30 analogues as potent and selective *Tg*CDPK1 inhibitors. Most of the compounds showed low nanomolar activity against the enzyme. These compounds also showed good efficacy against *T. gondii* cells, with the best compound **35** exhibiting an EC~50~ of 89 nM. Furthermore, no compound showed significant toxicity to mammalian cells at concentrations up to 30 μM. Compounds **34** and **35** also exhibited improved solubility and good pharmacokinetic properties. Compared to compound **1**, both **34** and **35** had improved efficacy in a mouse model of toxoplasmosis. These studies provide new lead compounds for further development of drugs for toxoplasmosis therapy.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsmedchemlett.5b00319](http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.5b00319).Synthesis and characterization data of compounds, biological assays, and structural studies ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.5b00319/suppl_file/ml5b00319_si_001.pdf))
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